Law switch improves Pfizer’s cash reserves

Pfizer's cash pile is enough to buy nearly all publicly traded US biotechnology companies, according to an analysis by Deutsche Bank.

  • E-Mail
By  Stuart Qualtrough Published  May 17, 2005

Pfizer's cash pile is enough to buy nearly all publicly traded US biotechnology companies, according to an analysis by Deutsche Bank. Recent US tax law changes prompting repatriated foreign profits have bolstered the coffers of the world's largest drugmaker and it plans to repatriate up to $38.9bn - and at least $28.3bn in foreign earnings.

Add a Comment

Your display name This field is mandatory

Your e-mail address This field is mandatory (Your e-mail address won't be published)

Security code